

**7<sup>th</sup> Annual Innovative Approaches to Brain Tumor Management - VIRTUAL**  
**Friday, February 11, 2022**  
**AGENDA**

- 7:55 a.m. Welcome & Announcements**  
*Zachary N. Litvack, M.D. & Kester Phillips, M.D.*
- 8 a.m. Advances in The Diagnosis, Evaluation, and Systemic Management of Leptomeningeal Metastasis**  
*Kester Phillips, M.D.*  
**Objectives:**
- Identify the pathophysiology and clinical manifestation of leptomeningeal metastasis
  - Identify emerging diagnostic tools for leptomeningeal metastasis
  - Identify emerging systemic therapeutic options for leptomeningeal carcinomatosis
- 8:15 a.m. Q&A**
- 8:20 a.m. Transiently Opening the Blood-Brain Barrier to Treat Malignancies: Challenges and Opportunities**  
*Matthew Smith-Cohn, D.O.*  
**Objectives:**
- Outline the challenges the blood-brain barrier poses in treating primary and secondary malignancies to the brain
  - Review treatment approaches being studied to transiently open the blood-brain barrier to increase drug delivery
- 8:35 a.m. Q&A**
- 8:40 a.m. Molecular Evaluation & Treatment of Gliomas**  
*Howard Colman, M.D.*  
**Objectives:**
- Identify and apply recent changes in glioma molecular characterization based on cIMPACT and WHO 2021 criteria
  - Describe the relationship between integrated histological/molecular diagnosis and appropriate therapy for gliomas
- 8:55 a.m. Q&A**
- 9 a.m. What's New in Surgery for Glioma?**  
*Alon Orlev, M.D.*  
**Objectives:**
- Outline latest evidence guiding surgical intervention for brain tumors
  - Describe when surgery is and is not indicated for primary or recurrent brain tumors
  - Identify alternatives and adjuncts to resection
- 9:15 a.m. Q&A**

- 9:20 a.m.**      **Update of Imaging in Brain Tumors**  
*David Olayinka Kamson, M.D., Ph.D.*  
**Objectives:**
- Outline ongoing imaging harmonization efforts
  - Describe new interpretations for old imaging techniques
  - Summarize novel experimental imaging approaches
- 9:35 a.m.**      **Q&A**
- 9:40 a.m.**      **Clinical and Molecular Determinants of Outcome for Non-Optic Pathway Gliomas in Adults with Neurofibromatosis Type 1**  
*Carlos Guillermo Romo, M.D.*  
**Objectives:**
- Outline the difference in clinical and molecular features of gliomas in people with NF1 compared to sporadic cases
  - Identify the treatment options and outcomes for adults with NF1 and a non-optic pathway glioma
- 9:55 a.m.**      **Q&A**
- 10 a.m.**        **Update on Immunotherapy of Gliomas**  
*Michael Lim, M.D.*  
**Objectives:**
- Describe the current state of immunotherapy for brain tumors
  - Identify the strategies to overcome glioma induced immunosuppression
- 10:15 a.m.**      **Q&A**
- 10:20 A.M.**     **Digital Spatial Profiling of GBM and Melanoma Tumors Treated with Neuroadjuvant Checkpoint**  
*Jim Heath, Ph.D.*  
**Objectives:**
- Outline how the cellular microenvironment of the tumor can be characterized
  - Describe how that characterization provides hypotheses for drug targets
  - Identify major differences between the microenvironment of melanoma tumors relative to GBM tumors
- 10:35 a.m.**      **Q&A**
- 10:40 a.m.**     **Targeting Cancer Stem Cells for Treatment of Glioblastoma** (*pre-recorded*)  
*Parvinder Hothi, Ph.D.*  
**Objectives:**
- Outline the role of cancer stem-like cells in glioblastomas
  - Outline the methods for culturing and viable storage of tumor stem cells
  - Explain the use of high-throughput drug screening in devising personalized treatments
- 10:55 a.m.**      **Q&A**

- 11 a.m. Incorporation of BRAF–Targeted Therapy into Neuro-Oncology Clinical Practice**  
*Karisa Schreck, M.D.*  
**Objectives:**
- Recognize molecular alterations for which BRAF–targeted therapy might be efficacious
  - Identify appropriate small molecule targeted therapy of clinical trials for an individual patient
  - Recognize toxicities of RAF–targeted therapy
- 11:15 a.m. Q&A**
- 11:20 a.m. Innovative Translational Research for Glioblastoma at The Ivy Center at Swedish Neuroscience Institute**  
*Charles Cobbs, M.D.*  
**Objectives:**
- Identify critical issues related to immunotherapy for glioblastoma
  - Identify key molecules for enhancing/targeting immunotherapy for glioblastoma
- 11:35 a.m. Q&A**
- 11:40 a.m. Primary CNS Lymphoma: An Overview of Management & Highlight of Advances**  
*Joe Mendez, M.D.*  
**Objectives:**
- Describe the initial evaluation/work-up of a patient with suspected newly diagnosed Primary CNS Lymphoma (PCNSL)
  - Identify how to outline the work up to evaluate for the extent of CNS involvement and for systemic involvement
  - Identify familiarities with the commonly used induction and consolidation therapies used to treat PCNSL
- 11:55 a.m. Q&A**
- 12 p.m. The 2021 WHO Classification of Tumors of the CNS**  
*Daniel Brown, M.D., MBA*  
**Objectives:**
- Outline both the major general changes as well as the specific changes in the more common taxonomic tumor categories
  - Recognize the developments that are advancing the role of molecular diagnostics in CNS tumor classification
  - Recognize shifting approaches to CNS nomenclature and grading emphasizing the importance of integrated diagnoses and layered reports
- 12:30 p.m. Q&A**
- 12:35 p.m. Proton Therapy for Leptomeningeal Disease**  
*Lia Moriguchi Halasz, M.D.*  
**Objectives:**
- Explain how proton therapy may improve the therapeutic index for patients with leptomeningeal disease
  - Examine published data on craniospinal irradiation for leptomeningeal metastases
  - Describe future directions in proton therapy for leptomeningeal disease
- 12:50 p.m. Q&A**
- 12:55 p.m. Survivorship Care in Neuro-Oncology**

*Akanksha Sharma, M.D.*

**Objectives:**

- Describe the importance of survivorship care for patients with brain tumors and their loved ones, emphasizing its unique place in cancer care
- Explain the key areas of importance as it applies to survivorship care for this patient population and the existing evidence on management for each
- Identify existing models of survivorship programs in neuro-oncology and a potential framework for the development of these programs at brain tumor centers

**1:10 p.m. Q&A**

**1:15 p.m. Adjourn**

Brain Tumor Agenda 2022 V22.docx

## ESTEEMED FACULTY

**Charles Cobbs, M.D.**  
**Course Co-Chair**

Director, Ben & Catherine Ivy Center  
Swedish Neuroscience Institute  
Seattle, Washington

**Kester Phillips, M.D.**  
**Course Co-Chair**

Neuro-oncologist  
Ben & Catherine Ivy Center  
Seattle, Washington

**Zachary N. Litvack, M.D., FAANS, FACS**  
**Course Co-Chair**

Director, Skull Base & Minimally Invasive Neurosurgery  
Swedish Neuroscience Institute  
Seattle, Washington

**Matthew Smith-Cohn, D.O.**  
**Course Co-Chair**

Neuro-oncologist  
Ben & Catherine Ivy Center  
Seattle, Washington

**Daniel Brown, M.D., MBA**

Chair, Department of Pathology & Laboratory Medicine  
Chief, Section of Neuropathology  
Medical Director HNL Lab Medicine  
Lehigh Valley Health Network  
Allentown, PA

**Howard Colman, M.D., Ph.D.**

Leader of Center for Neurologic Cancer  
Huntsman Cancer Institute  
Salt Lake City, Utah

**Lia Moriguchi Halasz, M.D.**

Associate Professor, Department of Radiation Oncology  
University of Washington School of Medicine  
Physician, UW Medicine & Seattle Cancer Care Alliance  
Seattle, Washington

**Jim Heath, Ph.D.**

President  
Institute Systems Biology  
Seattle, Washington

**Parvinder Hothi, Ph.D.**

Head Lab Scientist  
Ben & Catherine Ivy Center  
Swedish Neuroscience Institute  
Seattle, Washington

**David Olayinka Kamson, M.D., Ph.D.**

Assistant Professor of Neurology  
Department of Neuro-Oncology  
Johns Hopkins Medicine  
Baltimore, Maryland

**Michael Lim, M.D.**

Chair of Neurosurgery  
Stanford Hospital  
Palo Alto, California

**Joe Mendez, M.D.**

Assistant Professor of Neurosurgery  
University of Utah & Huntsman Cancer Institute  
Salt Lake City, Utah

**Alon Orlev, M.D.**

Neurosurgery Fellow  
Swedish Neuroscience Institute  
Seattle, Washington

**Carlos Guillermo Romo, M.D.**

Assistant Professor of Neurology  
Johns Hopkins Hospital  
Baltimore, Maryland

**Akanksha Sharma, M.D.**

Assistant Professor Neuro-Oncology Translational  
Neurosciences  
Providence Saint John's Health Center  
Santa Monica, California

**Karisa Shreck, M.D., Ph.D.**

Assistant Professor of Neurology  
The Johns Hopkins Hospital  
Baltimore, Maryland